News

Earlier, in 2005, Abraxis had entered into a license agreement with Taiho Pharma, under which Taiho Pharma got the right to market Abraxane in Japan. Taiho Pharma has

Somaxon Pharma claimed that Silenor binds with high affinity to histamine (H1) receptors. This is believed to be the mechanism by which Silenor promotes the maintenance of sleep.

CP404 is a calcium channel blocker used in oral dosage form to treat high-blood pressure. The novel mechanism for the drug therapy is based on the inhibition of

Mylan said that following the settlement agreement, it is expected to get the right to market Memantine HCl in the US on January 11, 2015, or earlier, under

Bupropion HCl SR tablets, used in the treatment of major depressive disorder, are the generic equivalent of GlaxoSmithKline’s Wellbutrin SR and are now available from Actavis in the

The study is part of a global collaboration and licensing agreement signed between Merrimack and Sanofi-aventis for MM-121 in 2009. Merrimack said that MM-121 is an antibody that

Oracal trial is a multinational, randomised, double-blind, placebo-controlled Phase III trial designed to enroll about 550 patients. Tarsa Therapeutics also stated that the independent Data Monitoring Committee (DMC)

NicOx was informed by the FDA that the review of the NDA is complete and that it does not approve the Naproxcinod application. FDA has recommended NicOx to

PharmCentre said that its presence along with other locations in US and Philippines offer 24×7 coverage of it’s services to customers. PharmCentre believes that call management plays a